Prior to funding Arthrosi Therapeutics, Dr. Yeh served as Vice President, Drug Development at Ignyta, where he led the progression of Ignyta’s multiple programs from Discovery to clinical development, and eventually to approval of Rozlytrek (entrectinib). He led the clinical pharmacology supports through all clinical phases, and NDA preparation of entrectinib. In addition, Dr. Yeh assisted the business development group in the sale of entrectinib to Roche.
Previously, Dr. Yeh served as Vice President, Translational Sciences at Ardea Biosciences, a member of the AstraZeneca Group, where he led the progression of Ardea’s internal development programs from concept to clinical development, and eventually to approval. He led the development teams through all clinical phases, IND, and NDA preparation. In addition, Dr. Yeh assisted the business development group in the sale of Ardea Biosciences to AstraZeneca, and in the successful licensing of refametinib to Bayer Healthcare. He supervised Ardea’s clinical pharmacology activities during clinical trials of refametinib, lesinurad, and verinurad.
Earlier in his career, Dr. Yeh managed all internal teams to support all development activities, and CRO monitoring. Dr. Yeh held positions of increasing responsibility at Valeant Pharmaceuticals, Ribapharm, and ICN Pharmaceuticals.
Dr. Yeh received a Ph.D. in chemistry and a B.S. in chemistry from Case Western University.